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Abstract 
Objective: The risk of cardiovascular morbidity and mortality is significantly increased in patients with diabetes; thus, 
it is important to determine whether glucose‑lowering therapy affects this risk over time. Changes in cardiovascu‑
lar risk markers were examined in patients with type 2 diabetes treated with exenatide twice daily (a glucagon‑like 
peptide‑1 receptor agonist) or glimepiride (a sulfonylurea) added to metformin in the EURopean EXenAtide (EUREXA) 
study.
Research design and methods: Patients with type 2 diabetes failing metformin were randomized to add‑on exena‑
tide twice daily (n = 515) or glimepiride (n = 514) until treatment failure defined by hemoglobin A1C. Anthropomor‑
phic measures, blood pressure (BP), heart rate, lipids, and high‑sensitivity C‑reactive protein (hsCRP) over time were 
evaluated.
Results: Over 36 months, twice‑daily exenatide was associated with improved body weight (−3.9 kg), waist circum‑
ference (−3.6 cm), systolic/diastolic BP (−2.5/−2.6 mmHg), high‑density lipoprotein (HDL)‑cholesterol (0.05 mmol/L), 
triglycerides (−0.2 mmol/L), and hsCRP (−1.7 mg/L). Heart rate did not increase (−0.3 beats/minute), and low‑density 
lipoprotein‑cholesterol (0.2 mmol/L) and total cholesterol (0.1 mmol/L) increased slightly. Between‑group differ‑
ences were significantly in favor of exenatide for body weight (P < 0.0001), waist circumference (P < 0.001), systolic BP 
(P < 0.001), diastolic BP (P = 0.023), HDL‑cholesterol (P = 0.001), and hsCRP (P = 0.004). Fewer patients randomized 
to exenatide twice daily versus glimepiride required the addition of at least one antihypertensive (20.4 vs 26.4 %; 
P = 0.026) or lipid‑lowering medication (8.4 vs 12.8 %; P = 0.025).
Conclusions: Add‑on exenatide twice daily was associated with significant, sustained improvement in several cardio‑
vascular risk markers in patients with type 2 diabetes versus glimepiride.
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Background
Type 2 diabetes significantly increases the risk of cardio-
vascular morbidity and mortality [1]. Clinical practice 
guidelines recommend the use of metformin as first-
line therapy for the management of type 2 diabetes [2, 
3]. In addition to lowering hemoglobin A1C, long-term 
data indicate that metformin also may be associated 
with risk reductions in cardiovascular outcomes [4]. As 
the majority of patients with type 2 diabetes often fail 
to achieve or maintain glycemic control with metformin 
alone, additional second-line therapies are often required 
[5]. Guideline-recommended add-on therapies to met-
formin include glucagon-like peptide-1 receptor agonists 
(GLP-1RAs), sulfonylureas, thiazolidinediones, dipep-
tidyl peptidase-4 inhibitors, sodium-glucose cotrans-
porter-2 inhibitors, and insulin [2, 3]. Because of a lack 
of comparative long-term outcomes studies of dual-agent 
combinations that assess cardiovascular measures, the 
cardiovascular risk benefits of add-on therapies to met-
formin are uncertain [6]. The measurement of various 
markers of cardiovascular risk (e.g., weight, waist circum-
ference, blood pressure [BP], glycemic markers, lipid lev-
els) in long-term studies of safety and efficacy may help 
to provide some guidance where long-term outcomes 
data are lacking.
The EURopean EXenAtide (EUREXA) study was the 
longest randomized, active-controlled, multinational 
study of a GLP-1RA with comparative treatment for up 
to 4.5  years with cardiovascular risk marker data col-
lected throughout the trial as secondary endpoints [7]. 
EUREXA compared the efficacy of exenatide twice daily 
versus glimepiride as second-line add-on therapy in 
patients with type 2 diabetes who had inadequate gly-
cemic control with metformin alone. Although patients 
in randomized controlled trials might differ in several 
aspects from patients in real-life clinical practice, patients 
enrolled in EUREXA were similar to typical patients with 
type 2 diabetes with regard to the prevalence of over-
weight/obesity, lipid abnormalities, and cardiovascular 
disease at baseline. Primary data on time to treatment 
failure for patients in the EUREXA study have been pub-
lished previously [7]. The objective of the current report 
was to examine changes in the cardiovascular risk mark-
ers, which included waist circumference, BP, serum 
lipids, and high-sensitivity C-reactive protein (hsCRP, 
as a surrogate marker of inflammation), over time with 
exenatide twice daily versus glimepiride.
Research design and methods
Study design and patients
EUREXA was a randomized, multicenter, open-label, 
two-arm parallel, active comparator-controlled trial 
of adult patients with type 2 diabetes with inadequate 
glycemic control using metformin [7]. Patients were 
enrolled in 14 countries (Austria, Czech Republic, Fin-
land, France, Germany, Hungary, Ireland, Israel, Italy, 
Mexico, Poland, Spain, Switzerland, and the United 
Kingdom). The study was performed with approval from 
institutional review boards in line with country-specific 
regulations, and in compliance with Good Clinical Prac-
tice and the principles of the Declaration of Helsinki. All 
patients provided signed informed consent.
Full inclusion and exclusion criteria were published 
previously [7]. Briefly, enrolled patients were aged 
18–85 years with type 2 diabetes, had a body mass index 
≥25 to <40  kg/m2 with stable body weight for at least 
3  months, were taking stable and maximum tolerated 
doses of metformin, and had inadequate glycemic control 
[A1C ≥6.5 % (48 mmol/mol) and <9.0 % (75 mmol/mol)]. 
Patients with active or untreated malignancy, renal or 
liver disease or dysfunction, chronic anemia or hemoglo-
binopathy, proliferative retinopathy or macular edema, or 
severe gastrointestinal disease were excluded.
Eligible patients were randomized in a 1:1 ratio, with 
stratification by A1C, to receive exenatide twice daily or 
glimepiride as add-on to current metformin treatment. 
Exenatide twice daily was initiated at 5  µg twice daily, 
increasing to 10 µg twice daily after 4 weeks, and was sub-
cutaneously administered by an injection pen in the abdo-
men, thigh, or upper arm within 60 min before meals that 
were at least 6 h apart. The recommended starting dose for 
glimepiride was 1  mg/day orally immediately before the 
morning meal, with titration every 4  weeks to the maxi-
mum tolerated dose, in accordance with the usual practice 
of the attending physician. As far as possible, patients con-
tinued to use the same formulation and dose of metformin 
throughout the study. There was no restriction on con-
comitant therapies, except for other anti-diabetes medica-
tions, weight-loss agents, and glucocorticoids.
Patients who experienced inadequate A1C control, 
defined as A1C concentration >9.0 % (75 mmol/mol) at 
any time after the first 6  months of randomized treat-
ment or >7.0 % (53 mmol/mol) at two consecutive study 
visits 3  months apart after the first 6  months of rand-
omized treatment, were discontinued and offered alter-
native treatment.
Study assessments
Patients visited the clinic at baseline, Week 4, and at 
3-month intervals after baseline until reaching the pri-
mary endpoint or study conclusion. A1C was measured 
every 3 months after baseline. Markers of cardiovascular 
risk included body weight (measured at baseline, Week 4, 
and every 3 months after baseline); waist circumference, 
BP, and heart rate (measured at baseline, Week 4, and 
every 6  months after baseline); and serum lipids (total 
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cholesterol, low-density lipoprotein (LDL)-cholesterol, 
high-density lipoprotein (HDL)-cholesterol, and tri-
glycerides) and hsCRP (measured at baseline and 1-year 
intervals after baseline). Safety assessments included 
data on hypoglycemic episodes (classified according to 
the American Diabetes Association recommendations 
[8]) and concomitant medications collected at each study 
visit as part of routine collection in the trial.
BP was determined three times, seated and after a 5-min 
rest, and the mean of the second and third measurements 
was recorded. All serum lipid and hsCRP assays were car-
ried out at a central laboratory (Interlab GmbH, Munich, 
Germany). A1C was determined by automated high-per-
formance liquid chromatography (Tosoh Bioscience Inc., 
San Francisco, CA, USA). Serum concentrations of total 
cholesterol, HDL-cholesterol, and triglycerides were deter-
mined using automated enzymatic colorimetric methods 
(Roche Diagnostics GmbH, Mannheim, Germany), with 
LDL-cholesterol calculated using the Friedewald for-
mula, and hsCRP measured by a high-sensitivity particle-
enhanced turbidimetric assay (Roche Diagnostics GmbH).
Statistical analysis
The intent-to-treat (ITT) efficacy population included 
randomized patients who received at least one dose of 
study treatment and had baseline and at least one post-
baseline measurement of A1C. Analyses of cardiovascu-
lar risk markers and safety measurements used an ITT 
safety population comprising all patients who received at 
least one dose of study drug. Continuous variables were 
analyzed by mixed model repeated measures (MMRM), 
with terms for treatment, study visit, and interactions, 
and including the baseline value as a covariate. Study 
visits with at least 25 % of randomized patients remain-
ing were included in MMRM analyses, and least-squares 
(LS) means and 95  % confidence intervals were derived 
from the model for each time point. Differences in 
rates of hypoglycemia, as episodes per year, were ana-
lyzed between groups using a negative binomial model. 
Between-group differences in use of concomitant medi-
cations were analyzed using Fisher’s exact test.
Ad hoc analyses for differences between treatment 
groups in proportions of patients meeting therapeutic 
goals at their final visit in the study for waist circumfer-
ence, systolic and diastolic BP (SBP and DBP, respec-
tively), and lipid concentrations were examined using a 
logistic regression model; therapeutic goals were those 
recommended by the American Diabetes Association [9].
Results
Baseline disposition and clinical characteristics
Patient disposition and baseline characteristics have 
been previously described [7]. Briefly, of 1029 patients 
randomized in the study, 515 were assigned to receive 
exenatide twice daily and 514 were assigned to receive 
glimepiride as an add-on to metformin. Of patients rand-
omized to exenatide twice daily and glimepiride, 511 and 
508 were included in the safety population, respectively. 
A total of 174 patients in the exenatide arm and 128 
patients in the glimepiride arm discontinued treatment; 
the most common reason for discontinuation in each 
arm was patient decision (70 and 50 patients, respec-
tively) [7]. Baseline characteristics were similar between 
the treatment groups except for fewer patients taking 
antihypertensive and lipid-lowering medications in the 
exenatide twice-daily group (Table 1). At the start of ran-
domized treatment, antihypertensive and lipid-lowering 
medications were reported for 65.4 and 45.6  %, respec-
tively, of the exenatide twice-daily group, and 70.3 and 
53.4  % of the glimepiride group. Overall, antihyperten-
sives were taken by 72.4 % of patients and lipid-lowering 
agents were taken by 54.4 % of patients during the study.
Body weight and waist circumference changes over time 
in exenatide twice daily‑ and glimepiride‑treated patients
Body weight decreased from baseline in the exenatide 
twice-daily group and increased in the glimepiride group 
at 36 months (Table 2; Fig. 1a). The between-group dif-
ference in the change from baseline was significantly 
in favor of exenatide twice daily at each visit from 6 to 
36  months (P  <  0.0001). Analysis by sex showed simi-
lar trends between males and females for body weight 
change and between-group differences. Significant 
between-group differences in favor of exenatide twice 
daily were observed in both males [LS mean (standard 
error [SE]), −5.3 (0.63) kg; P < 0.0001] and females [−5.2 
(0.68) kg; P < 0.0001].
Waist circumference decreased from baseline in 
the exenatide twice-daily group and increased in the 
glimepiride group at 36  months (Table  2; Fig.  1b). The 
between-group difference in the change from baseline 
was significant at each visit from 6 to 36 months in favor 
of exenatide twice daily (P < 0.001). Between-group dif-
ferences also were significant in both males (LS mean 
[SE], –5.0 [0.71] cm; P < 0.0001) and females [–4.0 (0.76) 
cm; P < 0.0001] at 36 months.
BP and heart rate changes over time in exenatide twice 
daily‑ and glimepiride‑treated patients
For the cardiovascular risk markers of BP and heart rate, 
only BP was significantly different between treatment 
groups. SBP significantly decreased from baseline in the 
exenatide twice-daily group and increased in the glime-
piride group at 36 months (P < 0.001) (Table 2; Fig. 2a). 
The between-group difference in the change from base-
line was significantly in favor of exenatide twice daily at 
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each visit from 6 to 36 months (P < 0.01) [7]. A signifi-
cantly higher proportion of patients achieved the SBP 
target of <130 mmHg in the exenatide twice-daily group 
compared with the glimepiride group at 36 months (43.2 
vs 34.7 %; P = 0.008). During the study treatment period, 
104 of 511 (20.4 %) patients in the exenatide twice-daily 
group compared with 134 of 508 (26.4 %) patients in the 
glimepiride group received at least one new antihyper-
tensive medication (P = 0.026).
DBP decreased from baseline over time in both treat-
ment groups with the largest decrease observed in exena-
tide-treated patients at 36  months (Table  2; Fig.  2b). 
Treatment with exenatide twice daily was associated with 
significantly greater decreases in DBP compared with 
glimepiride at each visit from 6 to 18 months (P < 0.01) 
and at 36 months (P = 0.023). DBP was significantly lower 
in female versus male patients overall [LS mean (SE), −1.1 
(0.27) vs 0.0 (0.25) mmHg; P = 0.0022]. The proportion of 
patients achieving the DBP goal of <80 mmHg was simi-
lar for the exenatide twice-daily and glimepiride groups at 
36 months (41.2 vs 41.7 %; P = 0.851).
Heart rate decreased from baseline in the exenatide 
twice-daily group at 36 months (Table 2; Fig. 2c) but the 
between-group difference was not significant.
Serum lipid changes over time in exenatide twice daily‑ 
and glimepiride‑treated patients
Total cholesterol increased from baseline in both 
treatment groups at 36  months (Table  2; Fig.  3a). No 
significant between-group differences were observed 
at any time point. The change from baseline in total 
cholesterol was significantly greater in female versus 
male patients overall [LS mean (SE), 0.24 (0.04) vs 0.02 
(0.03) mmol/L; P < 0.0001]. Serum LDL-cholesterol also 
increased from baseline at 36 months (Table 2; Fig. 3b). 
No significant between-group differences were detected 
at any time point. Similar to total cholesterol, the change 
from baseline in LDL-cholesterol was significantly 
greater in female versus male patients overall [LS mean 
(SE), 0.17 (0.03) vs 0.03 (0.03) mmol/L; P  =  0.0015]. 
The proportion of patients achieving the LDL-choles-
terol goal of <2.6  mmol/L was not significantly differ-
ent in glimepiride-treated patients in comparison with 
exenatide-treated patients at 36 months (56.2 vs 51.4 %; 
P = 0.101).
Serum HDL-cholesterol concentration increased 
slightly from baseline in exenatide-treated patients only 
at 36  months (Table  2; Fig.  4a). A significant between-
group difference in favor of exenatide was observed 
at 12 (P  =  0.002) and 36  months (P  =  0.001). Female 
patients had significantly higher changes in HDL-cho-
lesterol from baseline compared with males [LS mean 
(SE), 0.06 (0.01) vs 0.01 (0.01) mmol/L; P  =  0.0006]. 
A significantly greater proportion of exenatide-
treated patients achieved the HDL-cholesterol goal 
(>1.0  mmol/L for males, >1.3  mmol/L for females) 
than glimepiride-treated patients at 36 months (71.3 vs 
64.5 %; P = 0.021).
Table 1 Baseline characteristics of patients in the ITT safety population
* Age, sex, and A1C were measured for the ITT efficacy population only as per protocol, exenatide (n = 490), glimepiride (n = 487). BMI body mass index, HDL high-
density lipoprotein, ITT intent-to-treat, LDL low-density lipoprotein, SD standard deviation
Exenatide twice daily (n = 511) Glimepiride (n = 508)
Age (year), mean (SD)* 56 (10) 57 (9)
Male/female (%)* 56/44 52/48
Body weight (kg), mean (SD) 92.6 (16.6) 90.9 (15.1)
BMI (kg/m2), mean (SD) 32.5 (4.2) 32.2 (4.0)
Waist circumference (cm), mean (SD) 108.3 (11.8) 107.6 (11.5)
Systolic blood pressure (mmHg), mean (SD) 132.9 (15.7) 133.6 (15.4)
Diastolic blood pressure (mmHg), mean (SD) 80.5 (9.4) 79.8 (10.1)
Heart rate (beats per minute), mean (SD) 74.0 (9.3) 74.0 (10.1)
A1C (%), mean (SD)* 7.5 (0.7) 7.4 (0.7)
A1C (mmol/mol), mean (SD)* 58 (7.7) 57 (7.7)
Total cholesterol (mmol/L), mean (SD) 4.7 (1.0) 4.7 (1.0)
LDL‑cholesterol (mmol/L), mean (SD) 2.5 (0.8) 2.5 (0.8)
HDL‑cholesterol (mmol/L), mean (SD) 1.3 (0.3) 1.3 (0.3)
Triglycerides (mmol/L), mean (SD) 1.9 (1.2) 2.0 (1.3)
High sensitivity C‑reactive protein (mg/L), mean (SD) 4.8 (7.7) 4.2 (5.1)
Taking antihypertensive drugs (%) 65.4 70.3
Taking lipid‑lowering drugs (%) 45.6 53.4
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Table 2 LS mean (SE) change from baseline in cardiovascular risk markers at 36 months
CI confidence interval, HDL high-density lipoprotein, LDL low-density lipoprotein, LS least-squares, SE standard error
Exenatide (n = 511) Glimepiride (n = 508) P value for treatment 
difference
Body weight (kg)
 n 185 201
 LS mean (SE) −3.9 (0.33) 1.3 (0.32)
 95 % CI −4.6, −3.3 0.7, 1.9
 Treatment difference −5.2 (0.46) <0.0001
Waist circumference (cm)
 n 181 199
 LS mean (SE) −3.6 (0.38) 0.9 (0.36)
 95 % CI −4.4, −2.9 0.2, 1.6
 Treatment difference −4.5 (0.28) <0.001
Systolic blood pressure (mmHg)
 n 183 203
 LS mean (SE) −2.5 (0.89) 2.8 (0.85)
 95 % CI −4.2, −0.7 1.1, 4.4
 Treatment difference −5.2 (1.23) <0.001
Diastolic blood pressure (mmHg)
 n 183 203
 LS mean (SE) −2.6 (0.55) −0.9 (0.52)
 95 % CI −3.7, –1.5 −1.9, 0.2
 Treatment difference −1.7 (0.75) 0.023
Heart rate (beats per minute)
 n 181 199
 LS mean (SE) −0.3 (0.58) 0.4 (0.56)
 95 % CI −1.4, 0.9 −0.7, 1.5
 Treatment difference −0.7 (0.81) 0.374
Total cholesterol (mmol/L)
 n 178 193
 LS mean (SE) 0.1 (0.06) 0.1 (0.05)
 95 % CI 0.0, 0.3 0.0, 0.2
 Treatment difference 0.0 (0.08) 0.791
LDL‑cholesterol (mmol/L)
 n 171 184
 LS mean (SE) 0.2 (0.05) 0.1 (0.05)
 95 % CI 0.1, 0.3 0.0, 0.2
 Treatment difference 0.1 (0.07) 0.304
HDL‑cholesterol (mmol/L)
 n 178 195
 LS mean (SE) 0.05 (0.01) −0.02 (0.01)
 95 % CI 0.02, 0.07 −0.04, 0.01
 Treatment difference 0.06 (0.02) 0.001
Triglycerides (mmol/L)
 n 178 193
 LS mean (SE) −0.2 (0.06) 0.1 (0.06)
 95 % CI −0.3, −0.1 −0.1, 0.2
 Treatment difference −0.3 (0.09) 0.004
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Serum triglycerides decreased from baseline in exenatide-
treated patients and increased in the glimepiride group at 
36 months (Table 2; Fig. 4b). Significant between-group dif-
ferences in favor of exenatide were observed at 24 months 
(P = 0.017) and 36 months (P = 0.004). The proportion of 
all patients achieving the triglyceride target of <1.7 mmol/L 
was similar in the exenatide twice-daily and glimepiride 
treatment groups at 36 months (54.6 vs 52.4 %; P = 0.514).
During follow-up, significantly fewer patients in the 
exenatide twice-daily group required lipid-lowering 
agents compared with patients in the glimepiride group 
(8.4 vs 12.8 %; P = 0.025).
hsCRP changes over time in exenatide twice daily‑ 
and glimepiride‑treated patients
Serum concentration of hsCRP decreased from baseline 
in both treatment groups at 36  months, with a greater 
decrease observed in exenatide-treated patients [mean 
(standard deviation), −1.7 (6.56) vs −0.2 (4.01) mg/L]. A 
significant between-group difference in favor of exena-
tide twice daily was observed at each treatment visit from 
12 (P = 0.011) to 36 months (P = 0.004).
Hypoglycemia
Documented symptomatic hypoglycemia with blood 
glucose <3.9  mmol/L (<70  mg/dL) was reported during 
1 year of study treatment by 69 (13.5 %) and 198 (39.0 %) 
patients in the exenatide twice-daily and glimepiride 
groups, respectively (P  <  0.0001), and during 3  years of 
study treatment by 98 (19.2 %) and 237 (46.7 %) patients, 
respectively (P  <  0.0001). Documented asymptomatic 
hypoglycemia [blood glucose <3.9  mmol/L (<70  mg/
dL)] in exenatide twice-daily and glimepiride treatment 
groups was reported by 93 (18.2  %) and 215 (42.3  %) 
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Fig. 1 LS mean (SE) change from baseline (left panel) and treatment difference (right panel, exenatide twice daily − glimepiride) in body weight (a) 
and waist circumference (b) in randomized patients. BID twice daily, LS least‑squares, SE standard error
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Fig. 2 LS mean (SE) change from baseline (left panel) and treatment difference (right panel, exenatide twice daily − glimepiride) in systolic blood 
pressure (a), diastolic blood pressure (b), and heart rate (c) in randomized patients.  bpm beats per minute, BID twice daily, DBP diastolic blood pres‑
sure, HR heart rate, LS least‑squares, SBP systolic blood pressure, SE standard error
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patients, respectively, during 1 year (P < 0.0001), and 122 
(23.9  %) and 254 (50.0  %) patients, respectively, during 
3 years of study treatment (P < 0.0001).
Discussion
When first-line metformin is insufficient to maintain 
glycemic control in patients with type 2 diabetes, practi-
tioners are faced with an array of options for second-line 
add-on therapy. Either a GLP-1RA, such as exenatide, or 
a sulfonylurea, such as glimepiride, are viable second-line 
therapy options, and primary data from the long-term 
EUREXA study indicate that add-on exenatide twice 
daily provides significantly greater durability of glycemic 
control than add-on glimepiride [7]. Patients with type 2 
diabetes are at an increased risk of cardiovascular mor-
bidity and mortality [1]. We report that add-on exenatide 
twice daily was also associated with greater improve-
ment in several cardiovascular risk markers through 
36 months than add-on glimepiride. Significantly greater 
improvements in body weight, waist circumference, 
SBP, DBP, HDL-cholesterol, triglycerides, and hsCRP 
were observed in exenatide- compared with glimepir-
ide-treated patients, but changes in heart rate, total 
cholesterol, and LDL-cholesterol were similar between 
treatment groups. The improvements in cardiovascular 
risk markers observed with exenatide twice daily mirror 
improvements in body weight, BP, and lipids reported 
from long-term treatment with exenatide once weekly for 
up to 5 years [10, 11].
Very few studies have compared the long-term effi-
cacy and safety of GLP-1RAs with sulfonylureas for the 
improvement of glycemic control and cardiovascular 








































































































































































Fig. 3 LS mean (SE) change from baseline (left panel) and treatment difference (right panel, exenatide twice daily − glimepiride) in total cholesterol 
(a) and LDL‑cholesterol (b) in randomized patients. BID twice daily, LDL low‑density lipoprotein, LS least‑squares, SE standard error
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markers. The Liraglutide Effect for Action in Diabetes 
(LEAD)-3 trial examined the effects of liraglutide 1.2 
and 1.8 mg once daily compared with glimepiride 8 mg 
once daily for a 52-week controlled phase followed by a 
52-week open-label extension [12, 13]. Similar to long-
term treatment with exenatide twice daily, liraglutide 1.2 
and 1.8 mg treatment for 2 years was associated with sig-
nificantly improved cardiovascular risk markers includ-
ing body weight and waist circumference (P  ≤  0.0002) 
[13]. Decreases in SBP and DBP and increases in heart 
rate were not significant in patients treated with lira-
glutide, while exenatide was associated with significant 
decreases in SBP in the present study. Changes in lipids 
in patients treated with liraglutide were not reported 
in the original LEAD-3 study or in the 52-week exten-
sion [12, 13]. However, a recent 12-month retrospective 
cohort study of 115 liraglutide-treated patients indicated 
a positive benefit on lipids, with significant reductions 
from baseline in total cholesterol, LDL-cholesterol, and 
triglycerides (P  <  0.05), and a significant increase in 
HDL-cholesterol (P < 0.001) [14].
Differences in body weight between the two treatment 
groups were consistent with previous studies. The finding 
of weight loss with add-on exenatide twice daily in the 
long-term EUREXA study is supported by long-term data 
from two open-label extensions of clinical trials where 
sustained and progressive weight loss (mean change 
from baseline, −4.7 to −5.3 kg) up to 2–3 years’ duration 
were observed [15, 16]. The finding of weight gain with 
glimepiride treatment is also not unexpected. Data from 
two long-term studies observed body weight gain (mean 
change from baseline, 1.3  kg) with glimepiride when 












































































































































































Fig. 4 LS mean (SE) change from baseline (left panel) and treatment difference (right panel, exenatide twice daily − glimepiride) in HDL‑cholesterol 
(a) and triglycerides (b) in randomized patients. BID twice daily, HDL high‑density lipoprotein, LS least‑squares, SE standard error
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compared with two dipeptidyl peptidase-4 inhibitors [17, 
18].
Multiple studies have examined changes in waist cir-
cumference in patients treated with add-on exenatide or 
glimepiride but few inform on long-term changes. Over 
1 year, exenatide therapy added on to baseline metformin 
was associated with a significant mean reduction from 
baseline in waist circumference (−5  %) [19]. In a retro-
spective study of 179 patients treated with liraglutide or 
glimepiride in combination with metformin, liraglutide-
treated patients had a significantly greater mean reduc-
tion in waist circumference from baseline to 18 months 
compared with glimepiride (−3.0 vs 0.0  cm; P  <  0.001) 
[20]. One small randomized study comparing glimepir-
ide and thiazolidinedione treatment added to metformin 
observed an increase in waist circumference from base-
line of 1.86 cm with glimepiride [21]. In the present study 
we have found a difference of −4.5 cm of waist circum-
ference at 36 months between those patients treated with 
exenatide versus glimepiride. This finding may be largely 
explained by the observed changes in weight loss; how-
ever, there is also some evidence to suggest that the posi-
tive benefits of GLP-1RA therapy on waist circumference 
may be related to increased serum concentrations of 
atrial natriuretic peptide and B-type natriuretic peptide 
[22].
Increased levels of hsCRP have been shown to be related 
to features of the metabolic syndrome [23] and incident 
type 2 diabetes [24], as well as with increased total ather-
oma volume [25] and elevated coronary heart disease mor-
tality in patients with type 2 diabetes [26]. In the present 
study, both medications were associated with decreases 
in hsCRP through 36  months, with a greater decrease 
observed in the exenatide group. These findings confirm 
previous preliminary results from retrospective analyses 
[27], consistent with an association between exenatide and 
reduced hsCRP. It is unclear to date, however, whether 
this reduction in hsCRP levels is the result of the observed 
reversal in features of the metabolic syndrome or of a 
drug-specific, anti-inflammatory effect of exenatide.
Reducing BP is important in patients with type 2 dia-
betes to reduce risk of macrovascular and microvascular 
complications [28, 29]. Both SBP and DBP were reduced 
from baseline and maintained during 36 months of add-
on exenatide therapy. The mechanism of BP reduction in 
patients treated with exenatide has not been clearly delin-
eated. However, it appears that the short-term dynamics 
(arterial vasodilation) of BP is possibly related to the con-
comitant effects of reduced A1C and body weight with 
exenatide treatment [30, 31].
Recent studies are conflicting about the associa-
tion of weight changes with improvements in BP. In the 
Action for Health in Diabetes (Look AHEAD) study, 
1-year weight loss was found to be associated with sig-
nificant improvements in SBP through 4  years [32]. 
When looking at individual categories of weight loss in 
the Practice-based Opportunities for Weight Reduction 
(POWER-UP) trial, patients with weight loss of 10 % or 
more from baseline had smaller mean improvements in 
SBP and DBP compared with patients with no change in 
weight or weight gain through 24  months [33]. At least 
one analysis of eight clinical trials evaluating exenatide 
once-weekly treatment in patients with type 2 diabe-
tes showed greater decreases in SBP in patient quartiles 
with the greatest body weight loss from baseline; similar 
observations were also noted for reductions in LDL-cho-
lesterol, total cholesterol, and triglycerides [34]. In a ret-
rospective analysis evaluating liraglutide treatment over 
7.5  months, significant reductions in SBP from baseline 
(~7 mmHg; P < 0.001) were observed, but the reductions 
were not found to be associated with body weight loss 
(r = 0.22; P = 0.24) [35].
BP target achievement was low overall considering 
that 65 to 70  % of patients were taking antihyperten-
sive treatments at baseline. Less than half of all patients 
achieved the SBP (<130 mmHg) and DBP (<80 mmHg) 
targets [9]. One possible explanation for the low rates 
observed is that patients with type 2 diabetes mellitus 
are generally regarded as a population that is difficult to 
treat to guideline-recommended BP goals [36, 37]. Simi-
lar SBP goal achievement rates were observed across 
several clinical trials in an analysis of exenatide once 
weekly, although an incremental benefit was observed 
with exenatide compared with other oral glucose-low-
ering therapies [38]. Another explanation relates to 
the study design; there was no protocol requirement to 
standardize concomitant antihypertensive medications. 
Despite randomization, there was a disparity in the pro-
portions of patients taking concomitant medications at 
baseline. It is interesting that BP reductions were greater 
in the exenatide twice-daily group despite less use of 
antihypertensive medications at baseline and a signifi-
cantly lower proportion of patients receiving at least one 
new antihypertensive medication during the study.
Heart rate was decreased by less than 1 beat per min-
ute in patients treated with exenatide twice daily and 
the lack of change in heart rate is not unexpected. In a 
pooled analysis of studies comparing exenatide once 
weekly with other glucose-lowering medications, early 
increases in heart rate were observed with all GLP-1RA 
therapies [39]. At the endpoint observation, a clinically 
insignificant mean increase in heart rate of 0.9 beats 
per minute was observed in patients treated with exena-
tide twice daily, compared with increases of 2.8 and 2.6 
beats per minute for the longer-acting exenatide once 
weekly and liraglutide once daily, respectively. Inhibited 
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neurotransmission of vagal neurons, increased sympa-
thetic activity, and endothelium-induced vasodilation 
are all proposed mechanisms for heart rate increases that 
are observed with GLP-1RA therapy [40]. It is possible 
that shorter-acting exenatide twice daily has less impact 
on heart rate than longer-acting once-daily liraglutide or 
once-weekly exenatide because exenatide was present for 
short periods of time during the day and may not have 
been present when heart rate was measured [41, 42].
Total cholesterol and LDL-cholesterol increased from 
baseline in both treatment groups during 36  months of 
add-on therapy with no significant between-group differ-
ences observed, while a decrease in triglycerides and an 
increase in HDL-cholesterol were observed in patients 
treated with add-on exenatide twice daily. At baseline, the 
mean values for LDL- (2.5 mmol/L) and HDL-cholesterol 
(1.3 mmol/L) in the study population were already within 
recommended targets [LDL-cholesterol <2.6  mmol/L; 
HDL-cholesterol >1.1 (male) and >1.3 (female) mmol/L]. 
More than half of randomized patients were taking lipid-
lowering agents at baseline. As was seen with antihyper-
tensive medication, fewer patients on exenatide received 
additional lipid-lowering medication during the course 
of the study. At least one long-term observational fol-
low-up study of 82  weeks’ duration showed significant 
improvements from baseline in mean HDL-cholesterol 
and triglycerides with exenatide twice-daily therapy; 
improvements in total cholesterol and LDL-cholesterol 
were not found to be significant [43]. There is a lack of 
long-term data on the effects of glimepiride on lipid pro-
files. At least one short-term study of glimepiride added 
on to metformin showed that glimepiride had a neutral 
effect on lipids overall [44].
Despite the observed differences in biomarkers, no 
information is yet available on any differences in cardio-
vascular events between these therapies. Large retrospec-
tive database analyses and meta-analyses of randomized 
controlled trials have suggested either decreased rates 
or no increased risk of cardiovascular events in patients 
treated with GLP-1RAs [45–47], despite evidence that 
GLP-1RA therapy improves lipid profiles and a wide 
variety of markers of endothelial and vascular health 
[42, 48, 49]. Prospective clinical trials such as the ongo-
ing Exenatide Study of Cardiovascular Event Lowering 
(EXSCEL) (ClinicalTrials.gov identifier: NCT01144338) 
are required to confirm these findings. However, some 
data suggest that sulfonylureas have negative effects on 
cardiovascular risk and mortality [50–54], so a compara-
tive cardiovascular outcomes trial between exenatide 
twice daily and a sulfonylurea would provide interesting 
results.
Limitations of this study include the open-label design, 
which could have led to bias due to expectations of 
effects on cardiovascular markers. Furthermore, the 
study design of EUREXA was such that patients who did 
not maintain glycemic control exited the study over time, 
thus responders may have been selected for.
Conclusions
This secondary analysis of results from the EUREXA 
study showed that up to 36  months of treatment with 
add-on exenatide twice daily instead of glimepiride was 
associated with improved body weight, waist circumfer-
ence, BP, HDL-cholesterol, triglycerides, and hsCRP in 
patients with type 2 diabetes who failed metformin mon-
otherapy. These findings represent the longest controlled 
observation of the effects of exenatide twice daily on car-
diovascular risk markers to date and the only long-term 
data (36 months) for exenatide in comparison with a sul-
fonylurea. These data may assist physicians in choosing 
a second therapy for their patients with type 2 diabetes 
at increased risk of cardiovascular events. In addition, 
the positive effects of exenatide twice daily on BP, HDL-
cholesterol, and triglycerides may be associated with less 
antihypertensive and lipid-lowering medication use in 
this population. However, additional studies are needed 
to confirm this association and to evaluate any possible 
economic benefit.
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